BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38166647)

  • 1. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
    Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
    BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
    Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
    Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
    Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
    Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
    Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
    Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
    Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer.
    Chen B; Zhao H; Huang J; Lv H; Xu W; Nie C; Wang J; Zhao J; He Y; Wang S; Chen X
    BMC Geriatr; 2022 Dec; 22(1):987. PubMed ID: 36539696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
    Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.
    Hsu HC; Huang KC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang TS; Chen CC; Chao Y; Teng HW
    Sci Rep; 2021 Jul; 11(1):15370. PubMed ID: 34321583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.
    Lin CY; Lin TH; Chen CC; Chen MC; Chen CP
    PLoS One; 2018; 13(1):e0190497. PubMed ID: 29304109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
    Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
    Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
    Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
    Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.